WO2014016328A1 - Micro-organismes génétiquement modifiés pour produire des acides gras - Google Patents

Micro-organismes génétiquement modifiés pour produire des acides gras Download PDF

Info

Publication number
WO2014016328A1
WO2014016328A1 PCT/EP2013/065582 EP2013065582W WO2014016328A1 WO 2014016328 A1 WO2014016328 A1 WO 2014016328A1 EP 2013065582 W EP2013065582 W EP 2013065582W WO 2014016328 A1 WO2014016328 A1 WO 2014016328A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
micro
recombinant
fatty acid
production
Prior art date
Application number
PCT/EP2013/065582
Other languages
English (en)
Inventor
Ruud Alexander Weusthuis
John Van Der Oost
Gerrit Eggink
Original Assignee
Total Marketing Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Total Marketing Services filed Critical Total Marketing Services
Publication of WO2014016328A1 publication Critical patent/WO2014016328A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01035—3-Hydroxyacyl-CoA dehydrogenase (1.1.1.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/01008—Acyl-CoA dehydrogenase (NADP+) (1.3.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01016—Acetyl-CoA C-acyltransferase (2.3.1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01017—Enoyl-CoA hydratase (4.2.1.17), i.e. crotonase

Definitions

  • the application provides genetically engineered microorganisms for use in the production of fatty acids, alcohols and esters and their applications.
  • renewable fatty acids are obtained solely from plant oils.
  • Medium chain fatty acids (C8-C14) are typically sourced from coconut and palm oil, whereas longer chain saturated and unsaturated fatty acids are typically sourced from tallow, soy, corn or sunflower oil.
  • Fatty acids are widely used for food, personal care products, industrial applications (e.g., lubricants, adhesives, detergents and plastics), as well as increasingly as biofuels.
  • the demand for renewable fatty acids is rising and expanding.
  • the natural process of microbial fatty acid synthesis proceeds via a stepwise addition of two carbon units onto a growing acyl chain bound to acyl carrier protein (ACP).
  • ACP acyl carrier protein
  • the process begins as a condensation of acetyl-ACP and malonyl-ACP into acetoacetyl-ACP liberating C0 2 which drives the reaction forward.
  • the second step involves reduction of acetoacetyl-ACP to D-3-hydroxybutyryl-ACP using NADPH. Following a dehydration to crotonyl-ACP and another reduction using NADPH, butyryl-ACP is formed.
  • the chain elongation typically continues with further addition of malonyl-ACP until a C16 acyl chain is formed, which is then hydrolyzed by a thioesterase into a free C16 fatty acid.
  • Dellomonaco et al. (201 1 "Engineered reversal of the ⁇ -oxidation cycle for the synthesis of fuels and chemicals", Nature, 476: 355) suggest the engineering of a fatty acid biosynthesis pathway in Escherichia coli, called the “reversed beta oxidation pathway", that is believed to be more efficient than the native pathway in producing fatty acids and alcohols of various lengths and functionalities, which can in their turn be catalytically converted to chemicals and fuels.
  • Dellomonaco et al. do not provide a system to implement fatty acid production based on this pathway in a micro-organism.
  • fatty acids, alcohols and esters and products derived therefrom such as chemicals, fuels, lipids and/or oils.
  • novel and improved methods for the production of fatty acids and products derived therefrom, such as chemicals, fuels, lipids and/or oils which make use of these organisms.
  • the application provides micro-organisms that have been genetically modified for increased production of fatty acids by transformation with different genes involved in fatty acid metabolism of cellular organisms.
  • the application provides an alternative pathway to ensure fatty acid production in micro-organisms using the reversed beta-oxidation pathway. It has been determined that the gene ter from E. gracilis, encoding an enoyl-CoA reductase, in combination with the overexpression of recombinant genes fadB, fadA, and a thioesterase gene (such as for instance but not limited to fadM, tesA, tesB or yciA) allows to efficiently produce fatty acids by means of the reversed beta-oxidation cycle, without requiring the artificial production of stoechiometric amounts of reduced ferredoxin.
  • a thioesterase gene such as for instance but not limited to fadM, tesA, tesB or yciA
  • this enzyme uses NADH as a cofactor, which is naturally synthesized in sufficient amounts in the microorganisms by means of the glycolysis pathway.
  • beta oxidation of fatty acids in E. coli can be reversed by overexpression of the recombinant genes fadB, fadA, a thioesterase gene and ydiO (the latter being a ferredoxin-dependent trans enoyl CoA reductase)
  • this upstream fatty acid synthesis route only (efficiently) works when sufficient amounts of cofactor, i.e.
  • the application also provides alternative embodiments, wherein overexpression of the pyruvate:ferredoxin oxidoreductase gene or PFOR gene encoding a pyruvate ferredoxin oxidoreductase, in combination with the overexpression of recombinant genes fadB, fadA, a thioesterase gene (such as for instance but not limited to fadM, tesA, tesB or yciA) and ydiO in a micro-organism results in the production of sufficient amounts of reduced ferredoxin to catalyze trans enoyl CoA reductase and thereby complete the reversed beta- oxidation pathway.
  • the use of the ter gene as described above was found to be significantly more effective.
  • the application further provides strategies for optimizing the efficiency of fatty acid production in a micro-organism. Indeed, it has been found that introducing enzymes involved in the reversed beta oxidation pathway in oleaginous micro-organisms, more particularly oleaginous yeast, more particularly in yeast strains in which the endogenous fatty acid production and/or acetyl-CoA consumption pathways are blocked, ensures high yield production of fatty acids. Moreover, further reduction of fatty acid oxidation in said organism, stimulates the reverse beta oxidation pathway.
  • envisaged micro-organisms are yeast or fungi, whereby the yeast or fungi comprise at least one engineered gene deletion and/or inactivation in endogenous fatty acid accumulation, production, or consumption.
  • the micro-organisms contain an engineered gene deletion and/or inactivation in a gene encoding an enzyme such as but not limited to those selected from the group consisting of diacylglyceroltransferase (DGAT), phospholipid diacylglycerol transferase (PDAT), acyl-CoA dependent triacylglycerol synthase (DGA), acyl-CoA independent acyltransferase (LRO), acyl-CoA sterol acyltransferase (ARE) phospholipid- diacylglycerol acyltransferase (PLH), Diglyceride acyltransferase (or O-acyltransferase) (DGAT), diacylg
  • DGAT diacylg
  • the micro-organisms contain an engineered gene deletion and/or inactivation in one or more genes encoding enzymes involved in the triacylglycerol biosynthesis, such as phospholipid diacylglycerol transferase (PDAT), diacylglyceroltransferase (DGAT), or fatty acid synthase (FAS).
  • the micro-organisms contain an engineered gene deletion and/or inactivation in one or more genes encoding enzymes involved in the degradation of fatty acids, such as acyl-CoA oxidase (AOX) or acyl-CoA dehydrogenase, to stimulate the reverse beta-oxidation pathway.
  • AOX acyl-CoA oxidase
  • acyl-CoA dehydrogenase to stimulate the reverse beta-oxidation pathway.
  • the micro-organisms envisaged herein are genetically modified yeasts or fungi, such as but not limited to S. cerevisiae and Schizosaccharomyces pombe, and more particularly oleaginous yeasts or fungi, such as Mortierella ramanniana, Rhodutorula glutinis, Yarrowia lipolytica and Cryptococcus curvatus.
  • yeasts or fungi such as but not limited to S. cerevisiae and Schizosaccharomyces pombe, and more particularly oleaginous yeasts or fungi, such as Mortierella ramanniana, Rhodutorula glutinis, Yarrowia lipolytica and Cryptococcus curvatus.
  • the application provides different ways in which micro-organisms can be engineered to ensure efficient production of fatty acids, involving the modification of expression of one or more genes involved in fatty acid production pathway.
  • this involves the introduction of one or more recombinant genes encoding enzymes typically involved in fatty acid production pathway, such as fadB, fadA and a thioesterase gene, more particularly the introduction of a recombinant fadB , fadA and a thioesterase gene (such as for instance but not limited to fadM, tesA, tesB or yciA).
  • micro-organisms may be modified to eliminate repression of endogenous enzymes involved in beta oxidation by the product of the fadR gene. This is achieved by inactivation of the fadR gene.
  • Isolated micro-organisms are thus provided, which have been genetically modified for increased production of fatty acids, by introduction of and/or modification of expression of one or more genes of the beta oxidation pathway for the formation of fatty acids selected from a recombinant fadB gene, a recombinant fadA gene, a recombinant thioesterase gene, and whereby, in addition, production of the substrate for said thioesterase is ensured by the introduction of a recombinant gene encoding an NADH dependent trans- enoyl-CoA reductase.
  • This pathway ensures a functional reversal of the beta-oxidation cycle of fatty acids and can be performed anaerobically which significantly increases the yield of fatty acid production
  • the ter gene of Euglena gracilis is particularly suitable in the context of the effects envisaged herein.
  • the genetically modified micro-organisms envisaged herein comprise, in addition to one or more genes encoding enzymes from the beta oxidation pathway selected from a recombinant fadB gene, a recombinant fadA gene, a recombinant gene encoding a thioesterase, and a recombinant ter gene from Euglena gracilis.
  • the micro-organism is further modified to eliminate repression of the enzymes involved in beta oxidation by the product of the fadR gene.
  • the microorganisms are FadR negative strains.
  • the genetically engineered micro-organisms of the present invention comprise in addition to one or more genes selected from a recombinant fadB gene, a recombinant fadA gene and a recombinant thioesterase gene, a recombinant gene encoding an enoyl-CoA reductase, such as the ydiO gene and a recombinant pyruvate:ferredoxin oxidoreductase gene.
  • the yield of fatty acids can be further enhanced in the organisms described above comprising genes encoding enzymes involved in the reversed beta oxidation pathway, by inactivating endogenous genes of said organisms encoding proteins involved in an endogenous metabolic pathway which produces a metabolite other than the fatty acid of interest and/or wherein the endogenous metabolic pathway consumes the fatty acid.
  • the production of the metabolite other than the fatty acid of interest is reduced.
  • the microorganisms envisaged herein comprise, in addition to enzymes involved in the reversed beta oxidation pathway, at least one engineered gene deletion and/or inactivation of an endogenous pathway in which the fatty acid is consumed or produced or a gene encoding a product involved in an endogenous pathway which produces a metabolite other than the fatty acid of interest. Elimination of expression of such a gene increases fatty acid synthesis yield.
  • the micro-organisms envisaged herein are recombinant micro-organisms which comprise the above-mentioned combinations of recombinant foreign genes involved in fatty acid production and/or at least one engineered gene deletion and/or inactivation of an endogenous pathway in which the fatty acid is consumed or produced and/or a gene encoding an enzyme involved in an endogenous pathway which produces a metabolite other than the fatty acid of interest.
  • the micro-organisms envisaged herein further comprise at least one engineered gene deletion and/or inactivation of an endogenous lactic acid production pathway and/or an endogenous acetate production pathway, which for example may be an engineered gene deletion and/or inactivation in a gene encoding an enzyme such as those selected from the group consisting of D-lactate dehydrogenase (d-ldh), L-lactate dehydrogenase (l-ldh), phosphotransacetylase (pta), pyruvate decarboxylase (pdc) and pyruvate dehydrogenase (pdh) and any combination thereof.
  • an enzyme such as those selected from the group consisting of D-lactate dehydrogenase (d-ldh), L-lactate dehydrogenase (l-ldh), phosphotransacetylase (pta), pyruvate decarboxylase (pdc) and pyruvate dehydrogenase
  • the microorganisms further comprise at least one engineered gene deletion and/or inactivation of an endogenous lactic acid production pathway and/or an endogenous acetate production pathway, such as but not limited to at least one engineered gene deletion and/or inactivation of one or more lactate dehydrogenase (Idh) genes, phosphotransacetylase (pta), pyruvate decarboxylase (pdc) and/or pyruvate dehydrogenase (pdh) genes.
  • Idh lactate dehydrogenase
  • pta phosphotransacetylase
  • pdc pyruvate decarboxylase
  • pdh pyruvate dehydrogenase
  • the micro-organisms envisaged herein are genetically modified bacteria.
  • the micro-organisms may be applied to produce fatty acids on a large scale and with high yields. More particularly, the micro-organisms may be capable of producing fatty acids at a yield of at least 0.5 g/L from sugars, more particularly at least 2 g/L, or at least 5g/L from sugars under anaerobic conditions.
  • the micro-organisms envisaged herein are capable of converting monosaccharides, such as but not limited to glucose, xylose, arabinose, galactose, disaccharides, such as but not limited to maltose, sucrose, lactose, cellobiose, polyalcohols, such as but not limited to mannitol, sorbitol, glycerol, and mixtures thereof at a concentration of at least 10 g/L into fatty acids.
  • the application provides for the use of the genetically engineered micro-organisms described herein in the industrial production of one or more fatty acids, alcohols and/or esters or products derived therefrom.
  • the fatty acid production by the micro-organisms of the present invention is performed under anaerobic conditions.
  • the application provides methods for production of a composition comprising one or more fatty acids and/or one or more products derived therefrom involving the microorganisms disclosed herein.
  • such methods may comprise the steps of:
  • step (ii) culturing the micro-organism in the presence of pentose or hexose sugars under conditions suitable for the expression of said recombinant genes.
  • the culturing step (ii) of the methods for production described herein may be performed either completely or partially under anaerobic conditions.
  • compositions obtainable by methods described herein for increased production of a composition comprising one or more fatty acids and/or one or more products derived therefrom are provided.
  • the methods for producing one or more purified fatty acids, alcohols or esters are provided, which methods may comprise the steps of:
  • FIG. 1 Illustration of the use of the reversed beta oxidation pathway for fatty acid production according to a particular embodiment of the invention whereby genes fadA, fadB, fadM and yidO are overexpressed.
  • This approach requires the production of reduced ferredoxin stream upwards in order to catalyze the action of the ferredoxin-dependent trans enoyl CoA reductase.
  • this is ensured by introduction of a gene encoding a pyruvate ferredoxin oxidoreductase, such as the ydbK gene from E. coli; catalyzing a reaction with a sufficient rise in redox potential in order to ensure the production of reduced ferredoxin streamupwards in the reversed beta oxidation cycle.
  • Figure 2 Illustration of the use of the reversed beta oxidation pathway for fatty acid production according to a particular embodiment of the invention with indicated genes fadA, fadB, fadM and ter to be overexpressed and candidate genes for inactivation or gene deletion marked by red crosses.
  • Figure 3 Illustration of the use of the reversed beta oxidation pathway in yeast according to a particular embodiment of the invention, with indicated genes fadA, fadB, fadM and ter to be overexpressed and candidate genes for inactivation or gene deletion marked by red crosses.
  • Figure 4 Illustration of an exemplary method of a step-wise construction of a transformation vector pASK-IBA3C which can be used for the transformation of E. coli strains according to particular embodiments of the invention.
  • the four genes fadA, fadB, fadM and ter are cloned step by step into the expression vector.
  • Figure 5 Illustration of exemplary thioesterase activity of extracts of micro-organisms transformed with codon optimized fadM (codFADM) according to particular embodiments of the invention, confirming the efficient transformation with a thioesterase gene.
  • Grey triangles control.
  • Figure 6 Illustration of the use of the reversed beta oxidation pathway in yeast according to a particular embodiment of the invention, further illustrating the envisaged modifications in metabolic pathways.
  • the term “homology” denotes structural similarity between two macromolecules, particularly between two polypeptides or polynucleotides, from same or different taxons, wherein said similarity is due to shared ancestry.
  • the term “homologues” denotes so-related macromolecules having said structural similarity.
  • sequence identity between two polypeptides can be determined by optimally aligning (optimal alignment of two protein sequences is the alignment that maximises the sum of pair-scores less any penalty for introduced gaps; and may be preferably conducted by computerised implementations of algorithms, such as “Clustal” W using the alignment method of Wilbur and Lipman, 1983 (Proc. Natl. Acad. Sci. USA, 80: 726-730).
  • Alternative methods include “Gap” using the algorithm of Needleman and Wunsch 1970 (J Mol Biol 48: 443-453), or “Bestfit”, using the algorithm of Smith and Waterman 1981 (J Mol Biol 147: 195—197), as available in, e.g. , the GCGTM v.
  • the amino acid sequences of the polypeptides and scoring, on one hand, the number of positions in the alignment at which the polypeptides contain the same amino acid residue and, on the other hand, the number of positions in the alignment at which the two polypeptides differ in their sequence.
  • the two polypeptides differ in their sequence at a given position in the alignment when the polypeptides contain different amino acid residues at that position (amino acid substitution), or when one of the polypeptides contains an amino acid residue at that position while the other one does not or vice versa (amino acid insertion or deletion).
  • Sequence identity is calculated as the proportion (percentage) of positions in the alignment at which the polypeptides contain the same amino acid residue versus the total number of positions in the alignment.
  • the algorithm for performing sequence alignments and determination of sequence identity is one based on the Basic Local Alignment Search Tool (BLAST) originally described by Altschul et al. 1990 (J Mol Biol 215: 403-10), more particularly the "Blast 2 sequences” algorithm described by Tatusova and Madden 1999 (FEMS Microbiol Lett 174: 247-250), such as using defaults settings thereof.
  • BLAST Basic Local Alignment Search Tool
  • sequence similarity between two polypeptides can be determined by optimally aligning (see above) the amino acid sequences of the polypeptides and scoring, on one hand, the number of positions in the alignment at which the polypeptides contain the same or similar (i.e., conservatively substituted) amino acid residue and, on the other hand, the number of positions in the alignment at which the two polypeptides otherwise differ in their sequence.
  • the two polypeptides otherwise differ in their sequence at a given position in the alignment when the polypeptides contain non-conservative amino acid residues at that position, or when one of the polypeptides contains an amino acid residue at that position while the other one does not or vice versa (amino acid insertion or deletion).
  • Sequence similarity is calculated as the proportion (percentage) of positions in the alignment at which the polypeptides contain the same or similar amino acid residue versus the total number of positions in the alignment.
  • fatty acid refers to any of a large group of organic acids, especially those found in animal and vegetable fats and oils. Characteristically made up of saturated or unsaturated aliphatic compounds with an even number of carbon atoms, this group of acids includes palmitic, stearic, and oleic acids.
  • saturated fatty acid refers to any fatty acid in which all bonds between carbon atoms are all single bonds.
  • saturated fatty acid refers to any fatty acid in which at least one of the bonds between carbon atoms is a double bond.
  • organic acid refers to an organic compound with acidic properties. More particularly in the context of the present invention organic acid compounds are selected from the group consisting of acetic acid, lactic acid (2- hydroxypropionic acid), succinic acid, furandicarboxylic acid, fumaric acid, maleic acid, citric acid, glutamic acid, aspartic acid, acrylic acid, oxalic acid, and glucanic acid.
  • carboxylic acid refers to an organic acid characterized by the presence of at least one carboxyl group. Acids with two or more carboxyl groups are also referred to as dicarboxylic, tricarboxylic, etc. Examples of carboxylic acids include but are not limited to acetic acid, oxalic acid and mal(e)ic acid, and succinic acid.
  • lactic acid in this application refers to 2-hydroxypropionic acid in either the free acid or salt form. The salt form of lactic acid is referred to as "lactate" regardless of the neutralizing agent, i.e. calcium carbonate or ammonium hydroxide.
  • lactic acid can refer to either stereoisomeric form of lactic acid (L-lactic acid or D-lactic acid).
  • lactate can refer to either stereoisomeric form of lactate (L-lactate or D- lactate).
  • lactic acid production this includes the production of either a single stereoisomer of lactic acid or lactate or a mixture of both stereoisomers of lactic acid or lactate.
  • acetic acid in this application refers to the carboxylic acid with the chemical formula CH 3 C0 2 H (also written as CH 3 COOH) in either the free acid or salt form.
  • the salt form of acetic acid is referred to as "acetate".
  • Lactate dehydrogenase activity refers to the ability of the enzyme lactate dehydrogenase to catalyze the reaction of pyruvate to lactate. It will be clear to the skilled person that this enzyme is also able to catalyze this reaction in the opposite direction under suitable conditions. Lactate dehydrogenase enzymes include (but are not limited to) the enzymes categorized by the Enzyme Commission numbers EC1.1.1.27 and EC1.1.1.28.
  • Phosphotransacetylase activity refers to the ability of the enzyme phosphotransacetylase (also named phosphate acetyltransferase, acetyl-CoA: phosphate acetyltransferase, phosphoacylase, and PTA) to catalyze the reversible transfer of an acetyl group from acetyl coenzyme A to a phosphate, with formation of acetyl phosphate. It will be clear to the skilled person that this enzyme is also able to catalyze this reaction in the opposite direction under suitable conditions. Phosphotransacetylase enzymes include (but are not limited to) the enzymes categorized by the Enzyme Commission numbers EC2.3.1.8.
  • Pyruvate decarboxylase activity refers to the ability of the enzyme pyruvate decarboxylase (also named 2-oxo-acid carboxylase, alpha-ketoacid carboxylase, pyruvic decarboxylase, and PDC) to catalyze the conversion of pyruvate into acetaldehyde and carbon dioxide. Pyruvate decarboxylase depends on cofactors thiamine pyrophosphate (TPP) and magnesium. It will be clear to the skilled person that this enzyme is also able to catalyze this reaction in the opposite direction under suitable conditions. Pyruvate decarboxylase enzymes include (but are not limited to) the enzymes categorized by the Enzyme Commission numbers EC4.1.1.1.
  • PDH pyruvate dehydrogenase
  • EC 1.2.4.1 oxidoreductase
  • FadA gene encoding the protein FadA, which is a thiolase (3-ketoacyl-CoA thiolase (thiolase I) EC 2.3.1.16) involved in the beta oxidation of fatty acids. FadA cleaves 3-ketoacyl-CoA, resulting in shortening of the input acyl-CoA by two carbon atoms to give acetyl-CoA, in the beta oxidation of fatty acids.
  • FadA cleaves 3-ketoacyl-CoA, resulting in shortening of the input acyl-CoA by two carbon atoms to give acetyl-CoA, in the beta oxidation of fatty acids.
  • FadB (gene) refers to a gene encoding the protein FadB having L-3-hydroxyacyl-CoA dehydrogenase (EC1.1.1.35) and small-chain-length enoyl-CoA hydratase (cronotase) (EC4.2.1.17) activity. FadB converts enoyl-CoA to 3-ketoacyl-CoA via 3-hydroxylacyl-CoA through hydration and oxidation in the beta oxidation of fatty acids.
  • FadM gene encoding the protein FadM, which is thioesterase III (long-chain acyl-CoA thioesterase) (EC3.1 .2.-) FadM is involved in the beta oxidation of fatty acids.
  • Escherichia coli fatty acid oxidation complex refers to the tetrameric multienzyme complex FadA 2 FadB 2 formed by the proteins FadA and FadB in E.coli.
  • fusedAB operon refers to a nucleotide sequence contained in the
  • DNA insert of plasmid pK52 coding for the Escherichia coli fatty acid oxidation complex DNA insert of plasmid pK52 coding for the Escherichia coli fatty acid oxidation complex.
  • ferredoxin-dependent acyl-CoA dehydrogenase gene refers to the gene encoding the protein YdiO, a putative ferredoxin-dependent acyl-CoA dehydrogenase (EC1.3.1.8), an enzyme that catalyzes the conversion of enoyl-CoA to acylCoA.
  • ydiO (gene) refers to a ferredoxin-dependent acyl-CoA dehydrogenase gene from E. coli, which is a possible AraC-like regulator of the ydiQRSTD operon in E. coli.
  • Other names include trans enoyl CoA reductase.
  • pyruvate:ferredoxin oxidoreductase gene or "PFOR gene” as used herein refers to the gene encoding a pyruvate ferredoxin oxidoreductase (EC1.2.7.1 ), an enzyme that catalyzes the conversion of pyruvate into acetyl-CoA.
  • the three substrates of this enzyme are pyruvate, CoA, and oxidized ferredoxin, whereas its four products are acetyl-CoA, C0 2 , reduced ferredoxin, and H + .
  • This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with an iron-sulfur protein as acceptor.
  • the systematic name of this enzyme class is pyruvate:ferredoxin 2- oxidoreductase (CoA-acetylating).
  • Other names in common use include pyruvate oxidoreductase, pyruvate synthetase, pyruvate:ferredoxin oxidoreductase, and pyruvic- ferredoxin oxidoreductase.
  • the "ydbK (gene)" is a gene encoding a pyruvate :ferredoxin oxidoreductase in E. coli (Akthar et al. (2009) Metabolic Engineering 1 1 (3): 139-147).
  • ter (gene) refers to the gene encoding the protein TER, which is a trans- 2-enoyl-CoA reductase (EC1.3.1.44), an enzyme that catalyzes the conversion of enoyl- CoA to acyl-CoA under oxidation of NAD(P)H to NAD(P).
  • recombinant or “genetically modified” as used herein with reference to host organisms, microorganisms or cells, encompass such host organisms, microorganisms or cells into which a recombinant nucleic acid molecule has been introduced or which has been in another way genetically modified, as well as the recombinant progeny of such host organisms, micro-organism or cells. This includes both organisms in which endogenous gene sequences are introduced at a position other than their natural position in the genome and organisms in which endogenous gene sequences have been modified or deleted.
  • transformation encompasses the introduction or transfer of a foreign nucleic acid such as a recombinant nucleic acid into a host organism, microorganism or cell.
  • a foreign nucleic acid such as a recombinant nucleic acid
  • the so-introduced nucleic acid or the resulting deletion of endogenous nucleic acid is preferably maintained throughout the further growth and cell division of said host organism, microorganism or cell.
  • Any conventional gene transfer or genetic modification methods may be used to achieve transformation, such as without limitation electroporation, electro-permeation, chemical transformation, lipofection, virus- or bacteriophage-mediated transfection, etc.
  • gene refers to a nucleic acid sequence which contains a coding sequence, a promoter and any other regulatory regions required for expression in a host cell.
  • recombinant gene refers to a sequence which contains a coding sequence a promoter and any other regulatory regions required for expression in said host cell which is not present as such in said host cells. This includes endogenous gene sequences which are introduced at a position other than their natural position in the genome and/or which have been modified in the coding and/or regulatory sequence.
  • promoter refers to an untranslated sequence located within 50 bp upstream the transcription start site and which controls the start of transcription of the structural gene. Generally it is located within about 1 to 1000 bp, preferably 1-500 bp, especially 1-100 bp upstream (i.e., 5') to the translation start codon of a structural gene.
  • terminal refers to an untranslated sequence located downstream (i.e., 3') to the translation stop codon of a structural gene (generally within about 1 to 1000 bp, more typically 1 -500 base pairs and especially 1-100 base pairs) and which controls the end of transcription of the structural gene.
  • a promoter or terminator is "operatively linked" to a structural gene if its position in the genome relative to that of the structural gene is such that the promoter or terminator, as the case may be, performs its transcriptional control function.
  • the term “exogenous” refers to the fact that the gene or coding sequence under consideration originates from outside of the host organism of concern or study.
  • heterologous refers to the fact that the gene or coding sequence under consideration is not native or endogenous to the host but rather originates or has been cloned from a different cell type or from an organism of a different species than the recipient host.
  • mutant or “endogenous” is used herein with respect to genetic materials (e.g., a gene, promoter or terminator) that are found (apart from individual-to-individual mutations which do not affect function) within the genome of wild-type cells of the host strain.
  • genetic materials e.g., a gene, promoter or terminator
  • overexpression refers to the fact that it is expressed at a higher level than naturally in said host cell. This may imply that it is a foreign gene, not naturally expressed in the host cell or that the endogenous gene has been modified so as to increase expression in said host cell.
  • activation refers to the fact that the gene product is either not expressed or not active in said host cell. This typically implies that the endogenous gene has been modified so as to no longer allow expression in said host cell but may also imply that the gene has been modified to ensure that the gene product is no longer active.
  • nucleic acid sequence or part(s) thereof corresponds, by virtue of the genetic code of an organism in question, to a particular amino acid sequence, e.g., the amino acid sequence of a desired polypeptide or protein.
  • nucleic acids “encoding” a particular polypeptide or protein may encompass genomic, hnRNA, pre-mRNA, mRNA, cDNA, recombinant or synthetic nucleic acids.
  • a nucleic acid encoding a particular polypeptide or protein may comprise an open reading frame (ORF) encoding said polypeptide or protein.
  • ORF open reading frame
  • An "open reading frame” or “ORF” refers to a succession of coding nucleotide triplets (codons) starting with a translation initiation codon and closing with a translation termination codon known per se, and not containing any internal in-frame translation termination codon, and potentially capable of encoding a polypeptide.
  • the term may be synonymous with "coding sequence” as used in the art.
  • anaerobic conditions in the context of the present application in fact refer to conditions in which no air or free oxygen is present or provided.
  • micro-organisms are provided that are capable of increased production of fatty acids, alcohols, esters or other products derived there from.
  • the microorganism ensure a rate of fatty acid production which is sufficiently high to be industrially valuable.
  • the envisaged micro-organisms have been genetically modified to affect expression of one or more genes involved in fatty acid synthesis. More particularly they have been engineered to modify the expression of one or more genes encoding enzymes which ensure the reversed beta oxidation pathway, which operates with coenzyme A (CoA) thioester intermediates and directly uses acetyl-CoA for acyl-chain elongation (rather than first requiring ATP-dependent activation to malonyl-CoA), which are characteristics that enable product synthesis at high carbon and energy efficiency .
  • CoA coenzyme A
  • the (increased) fatty acid synthesis is ensured in the microorganisms envisaged herein by overexpression of one or more genes selected from the fadB gene, the fadA gene, and a thioesterase gene.
  • the microorganisms comprise a recombinant fadB gene, a recombinant fadA gene and/or a recombinant thioesterase gene.
  • Suitable examples of fadA, fadB and thioesterase genes envisaged in the context of the present invention are the fadA, fadB, fadM, tesA, tesB or yciA genes from E.
  • the thioesterase gene is selected from fadM, tesA, tesB and yciA. Methods for ensuring overexpression of endogenous genes and/or foreign genes are known to the skilled person and will be illustrated herein.
  • the modification of expression of these genes is ensured by eliminating the negative regulation of the beta oxidation enzymes by the FadR gene product.
  • the FadR gene product represses the activity of the beta oxidation enzymes in the presence of e.g. sugars. Eliminating this negative regulation can be ensured by inactivating an endogenous fadR gene, such that the genes involved in beta oxidation are constitutively expressed.
  • inactivation implies that all or part of the coding region of the gene is eliminated (deletion), or the gene or its promoter and/or terminator region is modified (such as by deletion, insertion, or mutation) so that the gene no longer produces an active enzyme, or produces an enzyme with severely reduced activity.
  • Inactivation further includes silencing such as by antisense, triple helix, and ribozyme approaches, all known to the skilled person.
  • FadR negative strains of E. coli are easily obtainable (e.g. Keio collection).
  • methods for selectively knocking-out genes are well known in the art.
  • the recombinant microorganisms are fadR mutants.
  • the microorganisms are characterized in that they have an inactivated fadR gene.
  • microorganisms of the present invention in which one or more of the fadB gene, the fadA gene, and the thioesterase gene are overexpressed, further comprise one or more modifications which ensure the reduction of enoyl-CoA in order to generate acyl-CoA, which is a substrate for the thioesterase gene.
  • fatty acid synthesis can also be achieved by microorganisms characterized by overexpression of one or more genes selected from the fadB gene, the fadA gene, and a gene encoding a thioesterase and further characterized by overexpression of an NADH dependent trans-enoyl-CoA reductase enzyme.
  • the microorganisms may be characterized by overexpression of a ter gene encoding a trans-2-enoyl-CoA reductase (EC1.3.1.44), which catalyzes the conversion of enoyl-CoA to acetylCoA under oxidation of NAD(P)H to NAD(P).
  • a recombinant ter gene may originate from any suitable source or organism.
  • Non-limiting examples are genes encoding TER enzymes originating from the yeast Saccharomyces cerevisiae (Song et al. 2009, J Exp. Bot 2009. April 60(6): 1839-1848), the spirochete Trepanoma denticola (Sara Tucci, William Martin, FEBS letters 581 (2007) 1561 -1566), mammalian peroxisomes (Das et al. 2000 Das AK, Uhler MD, Hajra AK. 2000. J.
  • the recombinant ter gene is a ter gene originating from Euglena gracilis (Hiroshi et al.1984 "Fatty acid synthesis in mitochondria of Euglena gracilis" Eur. J. Biochem.
  • terl having a high specificity for C4 compounds, ter2, having a high specificity for C6 and C8 compounds or ter3, having a high specificity for C6 compounds.
  • a suitable ter gene may thus be chosen depending on the desired length of fatty acid that is to be produced. Indeed, by relying on the preferred specificity for each of the TER enzymes, the length of the fatty acid to be produced can be controlled by selecting a particular TER enzyme with a particular specificity.
  • the microorganisms may thus comprise one or more recombinant genes selected from a recombinant fadB gene, a recombinant fadA gene, and a recombinant gene encoding a thioesterase, such as but not limited to fadM, tesA, tesB or yciA and, in addition a recombinant ter gene.
  • a thioesterase such as but not limited to fadM, tesA, tesB or yciA and, in addition a recombinant ter gene.
  • the microorganisms may be characterized by a) a recombinant fadB gene, b) a recombinant fadA gene, c) a recombinant gene encoding a thioesterase, and d) a recombinant ter gene.
  • a recombinant fadB gene a recombinant fadB gene
  • a recombinant fadA gene e.g., a recombinant gene encoding a thioesterase
  • a recombinant ter gene e.g., a recombinant ter gene that is characterized by a) a recombinant fadB gene, b) a recombinant fadA gene, c) a recombinant gene encoding a thioesterase, and d) a recombinant ter gene.
  • any species of micro-organism that can be suitably engineered with one or more of the above-disclosed combinations of recombinant genes, resulting in the (over)production of fatty acids, can be used in the context of the present invention.
  • the micro-organisms of the present invention are genetically modified bacteria or genetically modified yeasts or fungi. More particularly, microorganisms which can be cultivated anaerobically are of interest.
  • the micro-organism is an enterobacterium, such as Escherichia coli.
  • an efficient production of fatty acids can be obtained by using an oleaginous yeast, wherein the endogenous fatty acid production and/or consumption pathway has been modified and which is further modified by enzymes involved in the fatty acid production using the reversed beta oxidation pathway.
  • the host is selected from S. cerevisiae, Schizosaccharomyces pom be, Mortierella ramanniana, Rhodutorula glutinis, Yarrowia lipolytica and Cryptococcus curvatus.
  • the reversed beta-oxidation pathway is used by introduction a ferredoxin-dependent enoyl- CoA reductase.
  • a ferredoxin-dependent enoyl- CoA reductase As this requires the presence of reduced ferredoxin, it is demonstrated herein that efficient production of fatty acids is further ensured by reduction of enoyl-CoA by overexpression of a ferredoxin-dependent trans enoyl CoA reductase.
  • the nature of the ferredoxin-dependent trans enoyl CoA reductase is not critical to obtaining the envisaged effect.
  • the gene encoding a ferredoxin-dependent enoyl-CoA reductase is the ydiO gene from E. coli (EcoGene Accession Number: EG13974;
  • micro-organisms are engineered such that they are able to convert simple sugars to a fatty acid, and in particular embodiments to produce fatty acids at high yield.
  • these organisms are organisms which can be cultivated under anaerobic or quasi-anaerobic conditions, providing an additional advantage in the context of industrial production methods.
  • the microorganisms envisaged herein are characterized by overexpression of one or more genes selected from the fadB gene, the fadA gene, and a gene encoding a thioesterase and are further characterized by over-expression of a gene encoding an ferredoxin-dependent enoyl-CoA reductase and a pyruvate:ferredoxin oxidoreductase gene. Overexpression of these genes can be ensured by increasing expression of endogenous gene and/or expression of recombinant genes.
  • the microorganisms may comprise one or more recombinant genes selected from a recombinant fadB gene, a recombinant fadA gene, and a recombinant gene encoding a thioesterase and, in addition a recombinant gene encoding an ferredoxin-dependent enoyl-CoA reductase and a recombinant pyruvate:ferredoxin oxidoreductase gene.
  • the recombinant pyruvate:ferredoxin oxidoreductase gene or PFOR gene is the ydbK gene of E. coli (Akthar et al. (2009) Metabolic Engineering 1 1 (3): 139-147)(EcoGene Accession Number: EG13183; K-12 Gene Accession Number: ECK1374; MG1655 Gene Identifier: b1378). Indeed, it was found that the recombinant gene ydbK from E.
  • coli encoding a pyruvate:ferredoxin oxidoreductase, catalyzes a reaction with a sufficient rise in redox potential in order to ensure the production of reduced ferredoxin stream upwards in the reversed beta oxidation cycle, namely the conversion of pyruvate into acetyl-CoA.
  • the produced reduced ferredoxin is indispensable for the production of fatty acids by means of reversed beta-oxidation since it functions as a substrate for the conversion of enoyl-CoA to acetylCoA, which is in its turn needed as a direct substrate for fatty acid production by the fadM enzyme (see Figure 1 ).
  • the recombinant microorganism may comprise a) a recombinant fadB gene, b) a recombinant fadA gene, c) a recombinant gene encoding a thioesterase, d) a recombinant ydiO gene, and e) a recombinant ydbK gene.
  • the invention further envisages that the yield of fatty acids can be further enhanced by inactivating endogenous genes encoding proteins involved in an endogenous metabolic pathway which produces a metabolite other than the fatty acid of interest and/or wherein the endogenous metabolic pathway consumes or accumulates the fatty acid.
  • the micro-organisms engineered to produce fatty acids as described herein further comprise at least one engineered gene deletion and/or inactivation of an endogenous pathway in which the fatty acid is consumed and/or a gene encoding an enzyme involved in an endogenous pathway which produces a metabolite other than the fatty acid of interest.
  • the at least one engineered gene deletion or inactivation is in a gene encoding an enzyme selected from the group consisting of D-lactate dehydrogenase (d-ldh), L-lactate dehydrogenase (l-ldh), phosphotransacetylase (pta), pyruvate formate lyase (pfl), pyruvate decarboxylase (pdc), pyruvate dehydrogenase (pdh) and any combination thereof.
  • an enzyme selected from the group consisting of D-lactate dehydrogenase (d-ldh), L-lactate dehydrogenase (l-ldh), phosphotransacetylase (pta), pyruvate formate lyase (pfl), pyruvate decarboxylase (pdc), pyruvate dehydrogenase (pdh) and any combination thereof.
  • the micro-organisms envisaged herein comprise at least one engineered gene deletion and/or inactivation in an endogenous gene encoding lactate dehydrogenase, thereby preventing the production of the metabolite lactate (or lactic acid).
  • the micro-organisms envisaged herein comprise at least one engineered gene deletion or inactivation is in an endogenous gene encoding a phosphotransacetylase, thereby preventing the production of the metabolite acetate (or acetic acid).
  • the micro-organisms envisaged herein comprise at least one engineered gene deletion or inactivation is in an endogenous gene encoding a pyruvate formate lyase (pfl), thereby preventing the conversion of pyruvate into formate and acetyl CoA and channeling pyruvate to the beta-oxidation cycle.
  • a pyruvate formate lyase pfl
  • the deletion or inactivation of the endogenous gene is ensured by introduction of a recombinant gene involved in the reversed beta oxidation pathway.
  • the recombinant gene encoding a ferredoxin-dependent enoyl-CoA reductase is introduced into the endogenous gene encoding a pyruvate formate lyase (pfl) or a pyruvate dehydrogenase (pdh), thereby knocking out this gene.
  • the micro-organisms as envisaged herein comprise at least one engineered gene deletion and/or inactivation of an endogenous gene encoding a lactate dehydrogenase (Idh), a phosphotransacetylase (pta), or a pyruvate formate lyase (pfl) thereby preventing the production of the metabolites lactate (or lactic acid) and acetate (or acetic acid) and formate and channeling the substrate pyruvate to the beta-oxidation cycle.
  • a lactate dehydrogenase Idh
  • pta phosphotransacetylase
  • pfl pyruvate formate lyase
  • the micro-organisms as envisaged herein are of bacterial origin and comprise at least one engineered gene deletion and/or inactivation in the endogenous genes encoding a pyruvate decarboxylase (pdc) and pyruvate dehydrogenase (pdh) thereby preventing the conversion of pyruvate into acetaldehyde and acetyl-CoA, respectively, and channeling the substrate pyruvate to the beta-oxidation cycle.
  • pdc pyruvate decarboxylase
  • pdh pyruvate dehydrogenase
  • strains are provided which are characterized by the feature that the lactic acid, acetic acid (acetate) and/or ethanol production by said strain is at least reduced, more particularly is significantly reduced, compared to the background production in the corresponding wild-type strain.
  • the lactic acid, acetic acid or acetate production in the bacterial strains of the present invention is for instance at least 60% lower, preferably at least 80% lower and even more preferably at least 90% lower than in the corresponding wild-type strain.
  • the product of interest is an alcohol or an ester and the micro-organisms of the present invention contain further modifications for converting the fatty acid to the alcohol or ester of interest.
  • the micro-organisms envisaged herein are yeast or fungal micro-organisms, more particularly oleaginous yeast, which further comprise at least one engineered gene deletion and/or inactivation in an endogenous pathway, in which fatty acids are accumulated, consumed or which compete with the fatty acid synthesis pathway of interest.
  • the yeast micro-organism may be engineered to avoid the use of fatty acids in membrane production.
  • the engineered gene deletion and/or inactivation is in a gene encoding an enzyme such as but not limited to those selected from the group consisting of diacylglyceroltransferase (DGAT), phospholipid diacylglycerol transferase (PDAT), acyl-CoA dependent triacylglycerol synthase (DGA), acyl-CoA independent acyltransferase (LRO), acyl-CoA sterol acyltransferase (ARE) phospholipid-diacylglycerol acyltransferase (PLH), Diglyceride acyltransferase (or O- acyltransferase) (DGAT), diacylglycerol acyltransferase (DAGAT), fatty acid synthase (FAS), and any combination thereof.
  • DGAT diacylgly
  • the yeast or fungal micro-organisms comprise at least one engineered gene deletion and/or inactivation in an endogenous pathway, in which fatty acids are degenerated, in order to stimulate the reversed beta oxidation pathway.
  • the engineered gene deletion and/or inactivation is in a gene encoding acyl-CoA oxidase (AOX) or a gene with similar function, e.g. acyl-CoA dehydrogenase (AcDH).
  • the micro-organisms envisaged herein comprise a gene activation and/or gene deletion of one or more genes selected from DGAT1, DGAT2, LR01, ARE1 and ARE2, plhl, FAS, AOX, AcDH.
  • the micro-organisms envisaged herein are capable of growing on sugars and convert these sugars into fatty acids.
  • the micro-organisms of the invention can use monosaccharides such as glucose, xylose, arabinose, galactose, disaccharides as maltose, sucrose, lactose, cellobiose, polyalcohols like mannitol, sorbitol, glycerol, and mixtures thereof at a concentration at least 10 g/L for conversion into fatty acids.
  • the micro-organisms envisaged herein comprise additional genetic modifications which further the use of a particular substrate. More particularly, micro-organisms are envisaged which contain one or more genetic modifications furthering the consumption of arabinose.
  • the recombinant micro-organisms are capable of producing fatty acids when cultivated in a fermentable medium, even and especially under anaerobic or quasi-anaerobic conditions.
  • the micro-organisms may be capable of producing the fatty acid at a theoretical maximal yield (TM) of at 0.66 C/C with a practical maximal yield (PM) of at least 0.55 C/C and a productivity of at least 20g/l/h, such as at least 25g/l/h, at least 30g/l/h, such as at least 35g/l/h or even 40g/l/h under anaerobic or quasi-anaerobic conditions from pentose or hexose sugars.
  • TM theoretical maximal yield
  • PM practical maximal yield
  • the yield that can be obtained by the microorganisms is at least 0.5 g/L, most particularly at least 2 g/L.
  • the conversion yield of consumed sugar to fatty acid is at least 50%.
  • genetically modified or recombinant strains are provided, which are capable of producing fatty acids from pentose or hexose sugars at a yield of at least 5 g/L.
  • the fatty acids produced by the microorganisms envisaged herein are a mixture of different lengths. More particularly the fatty acids produced by the microorganisms may be any fatty acids ranging from C4 to C18, more particularly C4, C6, C8, C12, C14, C16, C18 fatty acid. As detailed above, when using recombinant ter genes, the length of the fatty acid produced by the micro-organism can be controlled by selection of the appropriate ter gene and/or thioesterase gene. In particular embodiments the fatty acids produced by the micro-organisms herein contain high amounts of C14 fatty acids.
  • the application relates to the use of the micro-organisms provided herein in the industrial production of fatty acids and/or products derived therefrom, such as alcohols' or esters.
  • genetically modified strains capable of producing fatty acids with increased yield or with a modified composition are of particular interest.
  • the micro-organisms may be capable of ensuring a high yield at limited production costs. Accordingly, in particular embodiments high yield methods of producing a composition comprising a fatty acid are provided.
  • methods comprising the steps of (i) providing a genetically modified or recombinant micro-organism as described herein, and (ii) culturing said micro-organism in the presence of a feedstock under conditions suitable for the production of the fatty acid or the product derived therefrom.
  • methods of producing a composition comprising specified amounts of one or more particular fatty acids are envisaged, such as, but not limited to C12, C14, C16 and C18 fatty acids.
  • methods are provided comprising the steps of (i) providing a genetically modified or recombinant microorganism as described herein, and (ii) culturing said micro-organism in the presence of a feedstock under conditions suitable for the production of the fatty acid or the product derived therefrom.
  • feedstocks are envisaged in the context of the present invention including but not limited to purified sugars (e.g.
  • cultivation is envisaged on hexose and/or pentose sugars as the sole carbon source.
  • compositions can be obtained by the methods envisaged herein which contain high levels of fatty acid and/or a specific composition of fatty acids.
  • the microorganism is capable of secreting the fatty acid into the medium.
  • the fatty acids are accumulated by the recombinant microorganisms in lipid granules within the host, and obtaining the fatty acids from the microorganisms may be necessary.
  • the fatty acids are secreted into the medium such that a composition comprising a relatively high titer of fatty acids can be obtained directly, by separating the microorganisms from the medium.
  • the relative titer of proteins in the compositions is reduced.
  • the cultivation of the micro-organisms is performed at least partially under anaerobic conditions.
  • methods for producing one or more fatty acids or a product derived therefrom, more particularly at high yield comprise the steps of (i) providing a genetically modified or recombinant micro-organism that has been modified to produce a fatty acid or a product derived therefrom at high yield from hexose or pentose sugars and (ii) culturing said micro-organism in the presence of hexose sugars.
  • the methods according to the present invention further comprise the step of recovering the fatty acid or product derived therefrom.
  • methods for producing one or more purified fatty acids or one or more other products derived therefrom, which methods comprise the steps of:
  • the methods for generating the recombinant microorganisms involve standard genetic modifications, for which well established methods are available to the skilled person.
  • the coding sequence encoding the enzyme of interest is placed under the transcriptional control of one or more promoters and one or more terminators, both of which are functional in the modified host cell.
  • Promoters and terminator sequences may be native to the host strain or exogenous to the cell.
  • Useful promoter and terminator sequences include those that are highly identical (i.e. have an identities score of 90% or more, especially 95% or more, most preferably 99% or more) in their functional portions compared to the functional portions of promoter and terminator sequences, respectively, that are native to the host strain, particularly when the insertion of the exogenous gene is targeted at a specific site in the strain's genome.
  • the promoter has an identity score at least 90%, 95% or 99% relative to a promoter that is native to a fungal gene. More particularly the promoter has an identity score of at least 90%, 95% or 99% compared to a promoter for a gene that is native to the host strain.
  • the terminator has an identity score of at least 90%, 95% or 99% compared to a terminator for a gene that is native to a fungus. The terminator may have an identity score of at least 90%, 95% or 99% with a terminator for a gene that is native to the host strain.
  • native (to the host strain) promoters and terminators can permit the targeted integration of the recombinant gene into specific loci of the host strain's genome, and for simultaneous integration the recombinant gene and deletion of another native gene. It is possible for the different recombinant coding sequences to be placed under the control of different types of promoters and/or terminators.
  • the recombinant gene may be integrated randomly into the host strain's genome or inserted at one or more targeted locations.
  • targeted locations include the loci of a gene that is desirably deleted or disrupted.
  • Suitable promoter sequences in the context of the present invention are known in the art and include for example an inducible tet promoter (Skerra, 1994), an inducible IPTG promoter (Jacob and Monod, 1961 ; J Mol Biol. 3:318-356).
  • Genetic modification of the host strains is accomplished in one or more steps via the design and construction of appropriate vectors and transformation of the host strain with those vectors. Electroporation and/or chemical (such as calcium chloride- or lithium acetate-based) transformation methods or Agrobacterium tumefaciens-med ⁇ aled transformation methods as known in the art can be used.
  • the vectors can either be cut with particular restriction enzymes or used as circular DNA.
  • the vector used for genetic modification of the host strains may be any vector so long as it can integrate in the genome of the host strain.
  • Vectors of the present invention can be operable as cloning vectors or expression vectors in the selected host strain. Numerous vectors are known to practitioners skilled in the art, and selection of an appropriate vector is a matter of choice.
  • the vectors may, for example, be the pASK-IBA3C expression vector (IBA-life sciences), pUR5750 transformation vector (de Groot et al. 1998 Nature Biotechnology 16, 839 - 842), the pCGHT3 transformation vector (Chambers et al. 1988 Gene, Volume 68, Issue 1 : 15; Scholtmeyer etal. 2001 Appl. Environ. Microbiol. 67(1 ): 481 ).
  • a vector is prepared that contains the (combination of) coding sequences of interest and associated promoter and terminator sequences.
  • the vector may contain restriction sites of various types for linearization or fragmentation.
  • Vectors may further contain a backbone portion (such as for propagation in E. coli) many of which are conveniently obtained from commercially available yeast or bacterial vectors.
  • the vector preferably contains one or more selection marker gene cassettes.
  • a "selection marker gene" is one that encodes a protein needed for the survival and/or growth of the transformed cell in a selective culture medium.
  • Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other toxins such as chloramphenicol, zeocin (sh ble gene from Streptoalloteichus hindustanus), genetecin, melibiase (MEL5), hygromycin (aminoglycoside antibiotic resistance gene from E. coli), ampicillin, tetracycline, or kanamycin (kanamycin resistance gene of Tn903), (b) complement auxotrophic deficiencies of the cell. Two prominent examples of auxotrophic deficiencies are the amino acid leucine deficiency (e.g. LEU2 gene) or uracil deficiency (e.g. URA3 gene).
  • ura3- Cells that are orotidine-5'-phosphate decarboxylase negative (ura3-) cannot grow on media lacking uracil.
  • a functional URA3 gene can be used as a marker on a cell having a uracil deficiency, and successful transformants can be selected on a medium lacking uracil. Only cells transformed with the functional URA3 gene are able to synthesize uracil and grow on such medium. If the wild-type strain does not have a uracil deficiency (as is the case with /. orientalis, for example.), an auxotrophic mutant having the deficiency must be made in order to use URA3 as a selection marker for the strain. Methods for accomplishing this are well known in the art.
  • selection makers include the zeocin resistance gene, G418 resistance gene, hygromycin resistance gene.
  • the selection marker cassette typically further includes a promoter and terminator sequence, operatively linked to the selection marker gene, and which are operable in the host strain.
  • Successful transformants can be selected for in known manner, by taking advantage of the attributes contributed by the marker gene, or by other characteristics (such as ability to produce fatty acids, inability to produce lactic acid or lactate, inability to produce acetic acid or acetate, or ability to grow on specific substrates) contributed by the inserted genes. Screening can be performed by PCR or Southern analysis to confirm that the desired insertions and deletions have taken place, to confirm copy number and to identify the point of integration of genes into the host strain's genome. Activity of the enzyme encoded by the inserted gene and/or lack of activity of enzyme encoded by the deleted gene can be confirmed using known assay methods.
  • deletions or inactivations envisaged herein can be accomplished by genetic engineering methods, forced evolution or mutagenesis and/or selection or screening. Indeed, the present state of the art provides a wide variety of techniques that can be used for the inactivation, deletion or replacement of genes. Such molecular techniques include but are not limited to:
  • the deletion or disruption of the endogenous gene is performed according to the method described by Oliveira et al (2008) (Appl Microbiol Biotechnol 80, 917-924)
  • the deletion or disruption of the endogenous gene may be performed by the simultaneous introduction of one or more functional structural genes, notably a gene encoding an enzyme involved in the production of the fatty acid of interest, such as, but not limited to one of the genes described above, inserted between the 5' and 3' flanking portions of one of the endogenous gene of the host strain.
  • the functional gene preferably includes functional promoter and terminator sequences operatively linked to the structural gene. This approach allows for the simultaneous deletion of the endogenous gene and insertion of the functional exogenous or heterologous gene.
  • the vector may include a selection marker gene instead of or in addition to the structural gene.
  • the selection marker gene is positioned on the vector between the 5' and 3' flanking portions of the endogenous gene(s) being targeted, and becomes inserted in the locus of the functional endogenous gene.
  • the use of a selection marker gene has the advantage of introducing a means of selecting for successful transformants.
  • a further aspect provides methods of obtaining micro-organisms with an increased and/or modified production of fatty acid, or a product derived therefrom, which methods comprise:
  • the step of transforming the micro-organism is described in detail hereinabove. As detailed above, different genetic modifications are envisaged which increase the yield of fatty acid production.
  • the step of transforming the microorganism with one or more recombinant nucleic acid sequences which ensure an increased production of the fatty acid (and/or the product derived therefrom includes the modification and/or inactivation of endogenous genes involved in the synthesis of other products the synthesis of which competes with fatty acid production in said organism, in order to increase the yield of fatty acid production.
  • the step of selecting a micro-organism capable of high yield fatty acid production is a selection step known to the skilled person and includes but is not limited to measuring activity of enzymes involved in the production of the fatty acid of interest. Additionally or alternatively in the methods according to the invention, the selection step can be based on reduced production of lactic acid or lactate, acetic acid or acetate or formic acid or formate, etc... In a further aspect, methods for producing a fatty acid or a product derived therefrom at high yield, especially under anaerobic or quasi anaerobic conditions are provided.
  • the methods of the present invention comprise the steps of obtaining a micro-organism which is can produce high concentrations of fatty acid by genetically modifying it to increase yield of the fatty acid and culturing the thus obtained microorganism in the presence of specific substrates or chemical building blocks.
  • the methods of the present invention comprise the steps of (i) modifying a strain such that it is capable of producing the fatty acid of interest, preferably at high yield, from a substrate such as pentose or hexose sugars; and (ii) culturing said strain in the presence of said suitable substrate.
  • the produced fatty acid is a carboxylic acid, even more particularly such as but not limited to butanoic acid, hexanoic acid, caprylic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid.
  • compositions comprising a specific amount of one or more specified fatty acids are envisaged. Indeed, it has been found that the fatty acids produced by the micro-organism may vary, depending on the genes that have been introduced. Methods for producing a micro-organism and methods of modifying said organism to increase fatty acid production yield and/or fatty acid composition are described hereinabove and illustrated in the Examples section.
  • the micro-organism or strain are cultivated in a medium that includes a sugar that is fermentable by the transformed strain.
  • the sugar may comprise monosaccharides, such as but not limited to glucose, xylose, arabinose, galactose, disaccharides, such as but not limited to maltose, sucrose, lactose, cellobiose, polyalcohols, such as but not limited to mannitol, sorbitol, glycerol, and mixtures thereof.
  • the micro-organism is modified to ensure the ability to use a specific substrate in the production of fatty acids.
  • enzymes can be added to the cultivation medium to ensure degradation of another substrate into fermentable hexose sugars.
  • the medium contains at least (the equivalent of) 5 g/L, at least 10 g/L, at least 20 g/L, at least 30g/L, more particularly at least 40g/L, and even more particularly at least 50 g/L glucose.
  • the medium comprises at least 100 g/L, more particularly between 100 and 500 g/L glucose.
  • the medium may optionally contain further nutrients as required by the particular strain, including inorganic nitrogen sources such as ammonia or ammonium salts, and the like, and minerals and the like.
  • the medium is a complete mineral medium comprising a hexose sugar as the only carbon source. The ability of the strains of the present invention to grow on this simple medium greatly reduces cost of cultivation and simplifies purification of the fatty acid produced.
  • Temperatures during each of the growth phase and the production phase may range from above the freezing temperature of the medium to about 50°C.
  • a preferred temperature, particularly during the production phase is from about 28-45°C.
  • the culturing step of the methods of the invention may be conducted aerobically, microaerobically or anaerobically. Quasi-anaerobic conditions or oxygen limited conditions, in which no oxygen is added during the process but dissolved oxygen is present in the medium at the start of the production process, can also be used.
  • the methods as envisaged herein comprise cultivation of micro-organisms (strains) which exhibit the ability to convert sugars to fatty acid (or another product derived therefrom of interest) under anaerobic or oxygen-limited conditions.
  • strains micro-organisms which exhibit the ability to convert sugars to fatty acid (or another product derived therefrom of interest) under anaerobic or oxygen-limited conditions.
  • the cultivation step of the methods according to this aspect can be conducted continuously, batch-wise, or some combination thereof.
  • the yield of fatty acid obtained by the tools and methods envisaged herein will depend on the cultivation conditions used.
  • the methods of producing fatty acids or products derived therefrom according to the present invention result in a yield of fatty acid (or derived product) that is at least 0.5 g/L, particularly at least 2 g/L, more particularly at least 5 g/L, particularly at least 50 g/L, and most particularly between 50-100 g/L.
  • the productivity of about 2-3 g/L/hour.
  • the micro-organisms envisaged herein are capable of converting at least 50%, more particularly at least 60%, even more particularly 75%, most particularly at least 95%, and up to 100% of the substrate consumed.
  • the yield obtained in particular embodiments of the methods of the present invention is at least 0.5g/g sugar, more particularly at least 0.6g/g sugar, but may be up to 0.95g/g sugar.
  • methods for producing a fatty acid or a product derived therefrom which, in addition to the steps detailed above further comprise the step of recovering the fatty acid of interest.
  • recovery of the fatty acid from cultivation medium in the methods of the present invention is greatly simplified in view of the fact that the organisms can be grown on a mineral medium containing only sugars as a carbon source. Suitable purification can be carried out by methods known to the person skilled in the art such as by using extraction, ion exchange resins, electrodialysis, nanofiltration, etc...
  • the methods may comprise the step of recovering said product of interest.
  • compositions obtainable by the methods for producing fatty acids or products derived therefrom described herein are provided, which compositions comprise one or more fatty acids and/or one or more products derived therefrom, such as for instance but not limited to butanoic acid, hexanoic acid, caprylic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, or products such as alcohols or esters obtained therefrom.
  • butanoic acid hexanoic acid
  • caprylic acid lauric acid
  • myristic acid palmitic acid, palmitoleic acid, stearic acid
  • oleic acid linoleic acid, linolenic acid
  • products such as alcohols or esters obtained therefrom.
  • Example 1 Fatty acid production in E. coli
  • a genetically modified E. coli was generated by ensuring overexpression of enzymes involved in the beta-oxidation pathway and expression of an NADH dependent enoyl-CoA reductase (ter).
  • FadA exhibiting 3-ketoacyl-CoA thiolase (EC 2.3.1.16) activity. FadB and FadA form the multienzyme complex (FadA 2 FadB 2 ).
  • TER from Euglena gracilis which is a frans-enoyl-CoA reductase.
  • the nucleotide sequence was codon optimized.
  • the four genes fadA, fadB, fadM and ter were cloned step by step into the pMA expression vector. Therefore, suitable oligonucleotides were generated and the genes were amplified by PCR using pMA::4 as template.
  • IPTG inducible expression vectors were constructed as listed in Table 1 Table 1. IPTG inducible expression vectors
  • Transformation was checked by streaking transformants on agar plate containing X-Gal and IPTG. After incubation at 37 °C over night, the streak of LacZ-containing cells is blue, whereas the streak of the control strain is not. Expression of genes was further tested by Western blot. Increase of fatty acid synthesis by reduction of production of side products
  • the genes for fatty acid production were transferred to E. coli and derivate deletion strains with a disrupted lactate dehydrogenase gene (AldhA, EC 1.1.1.28), with a disrupted phosphotransacetylase gene (Apta, EC 2.3.1.8), and with the double knockout.
  • E. coli wild type strain BW251 13 and derivate deletion strains with disrupted lactate dehydrogenase gene (AldhA, EC 1.1.1.28), phosphotransacetylase gene (Apta, EC 2.3.1.8), and double knock out (AldhA+Apta) were cultivated in mineral medium (Evans medium) under anaerobic conditions in serum flasks closed with a butyl rubber stopper. After 24 hours of incubation the substrate and product concentrations were determined. The results are shown in Table 2. Strongly reduced lactate production was observed in AldhA strains and strongly reduced acetate production in Apta strains. This resulted in the strong production of pyruvate by the double knock out mutant.
  • constructs were transferred to E. coli and derived deletion strains described above with disrupted lactate dehydrogenase gene (AldhA, EC 1.1.1.28), with disrupted phosphotransacetylase gene (Apta, EC 2.3.1.8), and a double knockout with disrupted lactate dehydrogenase gene (AldhA, EC 1.1.1.28) and disrupted phosphotransacetylase gene (Apta, EC 2.3.1.8)
  • the control strain for expression was E. coli BL21 (DE3).
  • E. coli BW251 13 Apta AldhA strain resulting in E. coli BW251 13 Apta AldhA+T7pol.
  • Expression analysis of double transformant strains E. coli BL21 and E. coli BW25113 Apta AldhA (+T7 pol.) containing the pACYCDuet and the pCOLADuet vectors showed expression of three genes fadA, fadB, fadM and ter (data not shown).
  • the fatty acids are extracted from the dry cells using chloroform or chloroform/methanol.
  • the fatty acids are methylated using TMSH (W. Butte, J. Chromatogr. 261. 1983) and analysed by GC.
  • An internal standard is used to quantify the peaks and a standard series of fatty acids is used to identify the individual fatty acids.
  • a Chloroform/methanol (1 :2) mixture was chosen as solvent for extraction of fatty acids from dry cells, as more types of fatty acids, and a higher concentration of fatty acids was detected after GC analysis than after use of chloroform alone as solvent.
  • Table 3 shows the amount of fatty acids (C16:0 palmitic acid, C16: 1 palmitoleic acid, C18:1 oleic acid) accumulated by the wild type E. coli strain and the double deletion strain after growth in LB or Evans medium under aerobic conditions at 37 °C.
  • the strains E. coli BL21 and E. coli BW25113 Apta AldhA (+T7 pol.) containing the genes fadA, fadB, Ter and fadM were analysed for fatty acid production. No extracellular fatty acids were found (results not shown).
  • the double knockout induced with IPTG showed a 2-3 fold higher intracellular fatty acid content with modified fatty acid composition (enriched in C14:0, C16:0 and C18:0), compared to the non-induced strain, suggesting that the synthetic pathway is active.
  • the fatty acid compositions of the biomass showed some differentiation. All transformants induced with IPTG showed lower C14:0, C17:0D and C19:0D contents and increased C16: 1 and C18:1 contents, as compared to the non-induced cultures. All transformants contained the FadM gene, such that it appears that this gene caused the observed differences. When all four enzymes of the reversed beta-oxidation pathway were present (i.e. the combination of FadABM+TER) a much larger impact on fatty acid composition was realized: it was the only transformant producing C12:0, and showed clearly increased levels of C14:0 and C18:0. These compounds were produced at the expense of C16:0, C17:0D and C18: 1.
  • the FadABM + TER transformant produced as only strain trace amounts of nine, sofar unknown, fatty acids. This strain also shows the largest increase in fatty acids content of the biomass (g/g) and in fatty acid concentration (g/g) upon induction with IPTG.
  • Example 2 Fatty acid production in yeast Identification of relevant genes The yeast C. curvatus is used as a model organism. The genes corresponding to DGAT (DGAT1 , DGAT2),PDAT, and FAS involved in the production of triacyl-glycerols were identified from the draft genome sequence for C. curvatus that is available at FBR. Also the GPD, pyrG, Ku70 and the gene corresponding to AOX involved in fatty acid degradation was identified.
  • Codon optimized synthetic genes encoding FadA, FadB, FadM and TER were ordered.
  • genes, gene fragments and the necessary marker genes which are necessary to build the vectors were cloned and sequenced.
  • Vectors were prepared by joining restriction fragments from the cloned PCR fragments or from the synthetic genes. Transformation vectors were built from a combination of a GPD promoter fragment, a gene to be expressed and a GPD terminator fragment. The following vectors were made:
  • GPD promoter-Hygromycin resistance gene- GPD terminator GPD promoter-Hygromycin resistance gene- GPD terminator
  • GPD promoter-Nourseothricin resistance gene- GPD terminator GNG
  • GPD promoter-FadA gene- GPD terminator GFadAG
  • GPD promoter-FadB gene- GPD terminator GFadBG
  • GPD promoter-FadM gene- GPD terminator GFadMG
  • GPD promoter-TER- GPD terminator GTERG
  • Knock out vectors aimed at insertion in a specific endogenous gene in order to inactivate this gene are prepared by selecting a 500 base pair fragment homologous to the 5'-part of the gene to be inactivated and cloning it in front of the first GPD promoter and a 500 base pair fragment homologous to the 3'-part of the gene to be inactivated cloned after of the last GPD terminator. The following vectors were generated for the C.
  • curvatus dgatl and dgat2 genes 5 GAT1 -GPD promoter-Hygromycin gene-GPD terminator-3'DGAT1 (DGAT1 -GHG) 5 GAT2-GPD promoter-Nourseothricine gene-GPD terminator-3'DGAT2 (DGAT2-GNG) 5'pyrG-GPD promoter-Nourseothricine gene-GPD terminator-3'pyrG (PyrG-GNG) 5'Ku70-GPD promoter-Nourseothricine gene-GPD terminator-3'Ku70 (Ku70-GNG)
  • the DGAT1 , DGAT2 and pyrG knockout vectors contained 500 bp overlap regions.
  • knock out vectors aimed at insertion within the FAS gene and thereby inactivating this gene are prepared by selecting a 500 base pair fragment homologous to the 5'-part of the gene to be inactivated and cloning it in front of the first GPD promoter and a 500 base pair fragment homologous to the 3'-part of the gene to be inactivated cloned after of the last GPD terminator.
  • the following vector was generated:
  • FadA, FadB, FadM, TER containing C. curvatus strain colonies were plated on oleic acid/tween80 containing plates and selected for oleic acid auxotrophy.
  • Knocking out the AOX gene reduces the fatty acid degradation in C. curvatus and thus enhances the effect of the reversed beta-oxidation pathway.
  • Knock out vectors aimed at insertion in the AOX gene and thereby inactivating this gene are prepared by selecting a 500 base pair fragment homologous to the 5'-part of the gene to be inactivated and cloning it in front of the first GPD promoter and a 500 base pair fragment homologous to the 3'-part of the gene to be inactivated cloned after of the last GPD terminator.
  • the following vector was generated:
  • FadA, FadB, FadM, TER containing C. curvatus strain After transformation of a FadA, FadB, FadM, TER containing C. curvatus strain, with the AOX knock out vector colonies were plated antibiotic containing plates and selected for AOX knock out by means of PCR. Increasing homologous recombination efficiency
  • the following vector was constructed containing 800 bp flanking region of the Ku70 gene and a NAT marker gene in between:
  • 10 ml YPD (in a 100 ml Erlenmeyer flask) is inoculated with a colony or with part of a glycerol stock and grow overnight (o/n) at 30 ° C and 250 rpm.
  • 1 ml from the o/n culture is used to inoculate 50 ml of YPD medium in a 250 ml Erlenmeyer flask and is grown for 3-4 hours at 30 ° C and 250 rpm. In this time the culture should reach an OD650 of 0.8-1. The culture is then put on ice.
  • the culture is then incubated approx. 12 minutes at 37 ° C in a waterbath.
  • the tubes are cooled quickly on ice and centrifuged 15 min. as before.
  • the buffer/DTT is discarded and replaced with 10 ml of cold sterile 270 mM Sucrose, 10 mM Tris/HCI pH 7.5, 1 mM MgCI2.
  • the pellet is carefully re-suspended and centrifuged again in the same way. The washing step is repeated.
  • the final pellet is re-suspended in a small volume of the Sucrose solution.
  • First approx. 0.5 ml is used and a cell suspension with a high viscosity is made which can just be handled with a normal 1 ml pipette tip.
  • 50 ⁇ competent cells are mixed with 5 ⁇ DNA* (in water) on ice in an Eppendorf tube.
  • the mix is transferred to a cuvette (precooled on ice) and the mixture is tapped down.
  • the pulse is provided and immediately thereafter 1 ml. of YPD medium (room temp.) is added.
  • the cells are mixed gently.
  • the cells are then transferred back to the Eppendorf tube and incubated 2-3 hr. at 30 ° C.
  • the DNA vector is used linearized or circular (standard plasmid isolates).
  • Inserting genes together with the selection marker is done by making one vector construct or by means of co-transformation. In the latter case depending on the gene used 1 -3 out of 10 co-transformants are obtained.
  • the amount of vector used is 100 - 1000 ng. of DNA per transformation resulting in 100 - 500 transformants / ⁇ g DNA.
  • the cells After incubations the cells are plated on YPD/ 1.5% agar + the proper antibiotic.
  • Antibiotics to be used are hygromycin, kanamycin, zeocin or nourseothricin. Optimal concentration of nourseothricin for selection was determined to be at 75 ⁇ g/ml.
  • the fatty acids are extracted from the dry cells using chloroform or chloroform/methanol.
  • the fatty acids are methylated using TMSH (W. Butte, J. Chromatogr. 261. 1983) and analysed by GC.
  • An internal standard is used to quantify the peaks and a standard series of fatty acids is used to identify the individual fatty acids.
  • fadA + fadB + fadM + TER Insertion of the alternative fatty acid biosynthesis pathway, fadA + fadB + fadM + TER, was done by co-transformation of a selectable marker gene (either the Hygromycin or Noursethricin resistance gene) with the 4 genes. After growth on selective plates colonies were initially screened for the presence of the heterologous genes by means of colony PCR. Colonies showing the presence of the genes were grown on a streak plate and single colonies were grown in liquid culture for DNA analysis. PCR on isolated DNA was used to confirm the genotype of the transformants. The strains obtained are listed in Table 6. Table 6. Strains and genotypes
  • the DNA was used for PCR reactions in order to confirm the genotype.
  • C1 -7, D1 -2 were selected for fatty acid analysis.
  • knock-outs can be used for further knock-out of the endogenous dgatl, dgat2 and fas genes using the knock-out vectors described above.
  • Colonies are identified wherein the dgatl , dgat2 and/or fas gene are effectively suppressed.
  • Cerulenin has been shown to inhibit fatty acid synthesis in a large number of fungi and yeasts. The inhibition occurs at the level of the FAS system. In order to maintain growth the inhibiting effect can partly be complemented by the addition of oleic acid to the growth medium.
  • Cerulenin was added at a concentration of 25 ⁇ g/ml).
  • Oleic acid/tween80 was added at 0.1 g/l, 0.25 g/l.
  • Example 3 The ferredoxin approach in E. coli. Vector construction
  • the homologous E. coli genes ydiO and ydbK were multiplied by means of PCR and cloned in a plasmid.
  • IPTG expression vectors were constructed comprising different combinations of fadA, fadB, fadM, ydiO and ydbK genes.
  • Transformation for expression the constructs were transferred to E. coli and derived deletion strains described above with disrupted lactate dehydrogenase gene (AldhA, EC 1.1.1.28), with disrupted phosphotransacetylase gene (Apta, EC 2.3.1.8), and a double knockout with disrupted lactate dehydrogenase gene (AldhA, EC 1.1.1.28) and disrupted phosphotransacetylase gene (Apta, EC 2.3.1.8).
  • the control strain for expression was E. coli BL21 (DE3).
  • IPTG inducible vectors need a T7-RNA polymerase to be expressed in the E. coli strain used, this gene is introduced into the E. co// BW25113 Apta AldhA strain resulting in E. coli BW251 13 Apta AldhA+T7pol.
  • the presence of the constructs was determined by cultivation in media containing the relevant antibiotic resistance markers. Expression analysis of the different strains is performed to check the production of the recombinant genes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des outils et des procédés pour produire des acides gras et leurs dérivés au moyen de micro-organismes génétiquement modifiés. Les outils et les procédés sont d'intérêt dans la production anaérobie d'acides gras à l'échelle industrielle.
PCT/EP2013/065582 2012-07-25 2013-07-24 Micro-organismes génétiquement modifiés pour produire des acides gras WO2014016328A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261675527P 2012-07-25 2012-07-25
EP12177771.8 2012-07-25
US61/675,527 2012-07-25
EP12177771 2012-07-25

Publications (1)

Publication Number Publication Date
WO2014016328A1 true WO2014016328A1 (fr) 2014-01-30

Family

ID=49996631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/065582 WO2014016328A1 (fr) 2012-07-25 2013-07-24 Micro-organismes génétiquement modifiés pour produire des acides gras

Country Status (1)

Country Link
WO (1) WO2014016328A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661597A (zh) * 2014-06-16 2017-05-10 英威达技术有限责任公司 用于产生戊二酸和戊二酸甲酯的方法
CN113917140A (zh) * 2021-10-28 2022-01-11 生工生物工程（上海）股份有限公司 一种快速筛选原核蛋白表达菌的方法
CN114107153A (zh) * 2021-11-26 2022-03-01 江南大学 一种生产己二酸的重组菌、构建方法和应用
US11692209B2 (en) * 2019-03-27 2023-07-04 Melt&Marble Ab Genetically modified fungal cells for overexpression of an acetyl-CoA carboxylase and a pyruvate carboxylase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111672A1 (fr) * 2008-03-05 2009-09-11 Genomatica, Inc. Organismes de production d’alcools primaires
WO2011062987A2 (fr) * 2009-11-17 2011-05-26 Ls9, Inc. Procédés et compositions de production d'hydrocarbures
WO2012109176A2 (fr) * 2011-02-07 2012-08-16 William Marsh Rice University Voie de bêta-oxydation inverse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111672A1 (fr) * 2008-03-05 2009-09-11 Genomatica, Inc. Organismes de production d’alcools primaires
WO2011062987A2 (fr) * 2009-11-17 2011-05-26 Ls9, Inc. Procédés et compositions de production d'hydrocarbures
WO2012109176A2 (fr) * 2011-02-07 2012-08-16 William Marsh Rice University Voie de bêta-oxydation inverse

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
AKTHAR ET AL., METABOLIC ENGINEERING, vol. 11, no. 3, 2009, pages 139 - 147
ALTSCHUL ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10
ARCHER ET AL., BASIC BIOTECHNOLOGY, 2006, pages 95 - 126
CHAMBERS ET AL., GENE, vol. 68, no. 1, 1988, pages 15
CLEMENTINA DELLOMONACO ET AL: "Engineered reversal of the [beta]-oxidation cycle for the synthesis of fuels and chemicals", NATURE, vol. 476, no. 7360, 1 January 2011 (2011-01-01), pages 355 - 359, XP055028708, ISSN: 0028-0836, DOI: 10.1038/nature10333 *
DAS AK; UHLER MD; HAJRA AK., J. BIOL.CHEM, vol. 275, 2000, pages 24333 - 24340
DE GROOT ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 839 - 842
DELLOMONACO ET AL.: "Engineered reversal of the P-oxidation cycle for the synthesis of fuels and chemicals", NATURE, vol. 476, 2011, pages 355
FINCHHAM, MICROBIOLOGICAL REVIEWS, vol. 53, 1989, pages 148 - 170
HIROSHI ET AL.: "Fatty acid synthesis in mitochondria of Euglena gracilis", EUR. J. BIOCHEM., vol. 142, 1984, pages 121 - 126
JACOB; MONOD, J MOL BIOL., vol. 3, 1961, pages 318 - 356
MEIKE HOFFMEISTER ET AL: "Mitochondrial trans-2-Enoyl-CoA Reductase of Wax Ester Fermentation from Euglena gracilis Defines a New Family of Enzymes Involved in Lipid Synthesis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 280, no. 6, 11 February 2005 (2005-02-11), pages 4329 - 4338, XP008131670, ISSN: 0021-9258, [retrieved on 20041129], DOI: 10.1074/JBC.M411010200 *
NEEDLEMAN; WUNSCH, J MOL BIOL, vol. 48, 1970, pages 443 - 453
OLIVEIRA ET AL., APPL MICROBIOL BIOTECHNOL, vol. 80, 2008, pages 917 - 924
PRASAD ET AL., ARCH. BIOCHEM BIOPHYS, vol. 237, no. 2, 1985, pages 535 - 544
SARA TUCCI; WILLIAM MARTIN, FEBS LETTERS, vol. 581, 2007, pages 1561 - 1566
SCHOLTMEYER ET AL., APPL. ENVIRON. MICROBIOL., vol. 67, no. 1, 2001, pages 481
SMITH; WATERMAN, J MOL BIOL, vol. 147, 1981, pages 195 - 197
SONG ET AL., J EXP. BOT, vol. 60, no. 6, April 2009 (2009-04-01), pages 1839 - 1848
SONG W-Q ET AL., J. EXP. BOT., vol. 60, no. 6, 2009, pages 1839 - 1848
TATUSOVA; MADDEN, FEMS MICROBIOL LETT, vol. 174, 1999, pages 247 - 250
W. BUTTE, J. CHROMATOGR., 1983, pages 261
WILBUR; LIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 726 - 730

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661597A (zh) * 2014-06-16 2017-05-10 英威达技术有限责任公司 用于产生戊二酸和戊二酸甲酯的方法
US11692209B2 (en) * 2019-03-27 2023-07-04 Melt&Marble Ab Genetically modified fungal cells for overexpression of an acetyl-CoA carboxylase and a pyruvate carboxylase
CN113917140A (zh) * 2021-10-28 2022-01-11 生工生物工程（上海）股份有限公司 一种快速筛选原核蛋白表达菌的方法
CN113917140B (zh) * 2021-10-28 2023-08-18 生工生物工程（上海）股份有限公司 一种快速筛选原核蛋白表达菌的方法
CN114107153A (zh) * 2021-11-26 2022-03-01 江南大学 一种生产己二酸的重组菌、构建方法和应用

Similar Documents

Publication Publication Date Title
US10465213B2 (en) Microorganisms and methods for the production of fatty acids and fatty acid derived products
CN102341502B (zh) 用于制备二醇的方法
Papanikolaou et al. Importance of the methyl-citrate cycle on glycerol metabolism in the yeast Yarrowia lipolytica
JP6061862B2 (ja) ３‐ヒドロキシプロピオン酸生産用の組成物及び方法
EP2673369B1 (fr) Voie de bêta-oxydation inverse
EP3022310B1 (fr) Micro-organismes et procédés pour la production d'acides gras et de produits dérivés d'acides gras
JP6294827B2 (ja) 操作された微生物および微生物油生成のための方法
US20240084340A1 (en) Heterologous production of 10-methylstearic acid
KR20120108538A (ko) 말로닉 세미알데히드 환원 경로를 이용한 3-하이드록시프로피온산의 생산방법
US20180002704A1 (en) Synthetic carbon fixation pathways
EP2807262A2 (fr) Procédés de production de succinate
US20160145599A1 (en) Mutant Yeasts Having an Increased Production of Lipids and of Citric Acid
US20200263210A1 (en) Microorganisms and methods for the production of glycolic acid and glycine via reverse glyoxylate shunt
JP2020506722A (ja) 目的分子を産生するための遺伝的に最適化された微生物
WO2014016328A1 (fr) Micro-organismes génétiquement modifiés pour produire des acides gras
CN105705650A (zh) 用于生物合成异丁烯酸盐的方法
WO2018203076A1 (fr) Micro-organismes modifiés et procédés de production de composés carbonés en c5 ramifiés
US10774349B2 (en) Alpha omega bifunctional fatty acids
Suryadarma et al. Metabolic engineering of Escherichia coli cells for ethanol production under aerobic conditions
KR101974221B1 (ko) 유기산 생산을 위한 재조합 미생물 및 이를 이용한 유기산 제조방법
US8735110B2 (en) Pseudomonas aeruginosa strain developed for improving fatty acid content, and method of manufacturing the same
WO2012103263A2 (fr) Compositions et méthodes pour la production de malate et de fumarate
US20210087571A1 (en) Acetyl-coa-derived biosynthesis
Haddouche et al. Yarrowia lipolytica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13750271

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13750271

Country of ref document: EP

Kind code of ref document: A1